Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (8)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
3 additional source qualifications - review before use
The label retains a CrCl-below-60 contraindication; the AGS 2023 older-adult criterion uses below 30. This difference does not establish safety for every patient between those values.
Before applying: Confirm population, lower-tract indication, duration and local policy. Document any departure from labeling; neither a source count nor this comparison selects a prescription.
The added historical MHRA advice differs in renal measure, cutoff and limited lower-UTI exception from the retained U.S. label and geriatric/institutional sources. It is not a new 2026 U.S. rule.
Before applying: Keep jurisdiction, infection site, source date and renal estimator attached to each recommendation. Do not substitute one numerical cutoff for another without clinical adjudication.
The label restriction, UCSF limited-data position and UK short-course exception differ in renal measure, setting and qualifications. UCSF is not an endorsement down to CrCl 30.
Before applying: Document jurisdiction and infection scope; preserve the UK multidrug-resistant lower-UTI and benefit-risk qualifications. Do not convert eGFR thresholds into CrCl cutoffs.
Also check: MACROBID label and older-adult criteria use different renal thresholds; Nitrofurantoin: U.K. indexed-eGFR advice is not the U.S. CrCl label; Nitrofurantoin: label, UCSF and UK guidance remain distinct
Official source
MACROBID renal contraindication - selected label
Product / population
MACROBID nitrofurantoin monohydrate/macrocrystals, oral. Selected restriction, not a complete antibiotic regimen.
Renal measure
CrCl, mL/min, plus qualitative anuria/oliguria and serum-creatinine criteria.
Renal dosing, restrictions and evidence limits
The selected MACROBID label contraindicates use with anuria, oliguria or significant renal impairment, including CrCl below 60 mL/min or clinically important serum-creatinine elevation. It identifies increased toxicity from impaired excretion. Monitor renal function with long-term treatment; pulmonary, hepatic and peripheral-neuropathy risks remain relevant. This label restriction differs from the separately displayed older-adult professional criterion.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Nitrofurantoin - UCSF cystitis guidance; selected source sections, not a full prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage. Retrieved: 2026-09-08
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
professional criterion vs label
MACROBID label and older-adult criteria use different renal thresholds
The label retains a CrCl-below-60 contraindication; the AGS 2023 older-adult criterion uses below 30. This difference does not establish safety for every patient between those values.
How to use this: Confirm population, lower-tract indication, duration and local policy. Document any departure from labeling; neither a source count nor this comparison selects a prescription.
Nitrofurantoin: U.K. indexed-eGFR advice is not the U.S. CrCl label
The added historical MHRA advice differs in renal measure, cutoff and limited lower-UTI exception from the retained U.S. label and geriatric/institutional sources. It is not a new 2026 U.S. rule.
How to use this: Keep jurisdiction, infection site, source date and renal estimator attached to each recommendation. Do not substitute one numerical cutoff for another without clinical adjudication.
Nitrofurantoin: label, UCSF and UK guidance remain distinct
The label restriction, UCSF limited-data position and UK short-course exception differ in renal measure, setting and qualifications. UCSF is not an endorsement down to CrCl 30.
How to use this: Document jurisdiction and infection scope; preserve the UK multidrug-resistant lower-UTI and benefit-risk qualifications. Do not convert eGFR thresholds into CrCl cutoffs.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
MACROBID renal contraindication - selected label
MACROBID nitrofurantoin monohydrate/macrocrystals, oral. Selected restriction, not a complete antibiotic regimen.
Method: CrCl, mL/min, plus qualitative anuria/oliguria and serum-creatinine criteria.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Important source distinctions
The historical renal cutoff is preserved. Current product labeling and professional recommendations may use different thresholds; do not silently reconcile them.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/nitrofurantoin/
Usual Dosing (Adults)
Macrodantin: 50-100 mg four times daily, with the lower dose for uncomplicated UTI. Take with food to improve absorption and sometimes tolerability. Macrobid: 100 mg every 12 hours.
GRPH-nitrofurantoin-01 · Source section: Usual Dosing (Adults)Renal section finder
Renal Dosing
Original bands: CrCl above 60 mL/min, normal dose; 0-59, avoid. The source does not explicitly assign exactly 60 mL/min.
DailyMed / NLM; manufacturer prescribing information · MACROBID nitrofurantoin monohydrate/macrocrystals, oral. Selected restriction, not a complete antibiotic regimen.
Renal method: CrCl, mL/min, plus qualitative anuria/oliguria and serum-creatinine criteria. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The selected MACROBID label contraindicates use with anuria, oliguria or significant renal impairment, including CrCl below 60 mL/min or clinically important serum-creatinine elevation. It identifies increased toxicity from impaired excretion. Monitor renal function with long-term treatment; pulmonary, hepatic and peripheral-neuropathy risks remain relevant. This label restriction differs from the separately displayed older-adult professional criterion.
GlobalRPh-hosted RX List · MACROBID monohydrate/macrocrystals for lower urinary tract infection, not pyelonephritis.
Renal method: CrCl, mL/min; equation not specified in the selected subsection. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
This source contraindicates use with anuria, oliguria, CrCl below 60 mL/min, or clinically significant elevated serum creatinine, because impaired excretion raises toxicity risk. Its labeled adult/over-12 regimen is 100 mg orally every 12 hours with food for seven days, but that regimen does not override the renal contraindication. The product is not indicated for pyelonephritis or perinephric abscess. Any different guideline cutoff needs a separately identified source and clinical adjudication, not silent replacement.
GlobalRPh-hosted RX List · Nitrofurantoin - MACROBID label restrictions; selected source sections, not a full prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The retrieved MACROBID label lists anuria, oliguria and significant renal impairment, including CrCl <60 mL/min or clinically significant serum-creatinine elevation, as contraindications. Renal impairment also increases neuropathy concern; monitor renal function during long-term therapy. Keep this label position distinct from professional or non-US guidance with different thresholds. A toxicity warning is not a validated reduced-dose strategy.
RDM48-rxlist-nitrofurantoin-bc3599c9be-C1 · Source locator: Contraindications; neuropathy and geriatric renal warnings.
Renal method: CrCl, mL/min. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Above CrCl 60, the institution lists 100 mg orally every 12 hours for cystitis treatment and 100 mg daily for prophylaxis. Below CrCl 60, evidence is limited and alternatives should be considered. Hemodialysis dosing data are also limited; consider alternatives. The source does not supply a validated lower-cutoff or dialysis regimen.
RDM33-professional-nitrofurantoin-C1 · Source locator: Adult non-dialysis and dialysis tables.
American Geriatrics Society expert panel · Adults aged 65 years and older; AGS 2023 geriatric criteria, not universal adult guidance.
Renal method: CrCl, mL/min. Source date: 2023 AGS Beers Criteria, published May 4, 2023 Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For older adults, the 2023 AGS criterion advises avoiding nitrofurantoin below CrCl 30 mL/min. Pulmonary, hepatic and neuropathy risks are emphasized, especially with long-term use. This is a geriatric prescribing criterion, not an FDA label revision or a dialysis regimen.
U.K. Medicines and Healthcare products Regulatory Agency (MHRA) · U.K. MHRA safety advice for nitrofurantoin; jurisdiction-specific comparison, not a replacement U.S. label.
Renal method: Indexed eGFR, mL/min/1.73 m2; not interchangeable with U.S. label CrCl. Source date: Article: September 2014; GOV.UK publication 2015-02-12. Selected advice rechecked 2026-09-08; not presented as a new 2026 guideline. Retrieved: 2026-09-08
Regulatory safety communication. This is a safety restriction, not a dose-adjustment strategy or evidence that a reduced dose is safe.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The MHRA advice generally contraindicates use below eGFR 45. A cautious 3 to 7 day course at eGFR 30 to 44 is reserved for lower UTI with suspected or proven multidrug-resistant pathogens when benefits outweigh risks. Do not use this exception for upper UTI or urinary-source sepsis. Monitor pulmonary, hepatic, neurological, hematological and gastrointestinal adverse effects.
RDM44-professional-nitrofurantoin-192ec1ebb9-C1 · Source locator: Advice for healthcare professionals, lines 74-80.
Source-specific limits
Retain U.S. label, geriatric and institutional recommendations separately. Different measures, settings and source dates are not numerical votes.
University of California San Francisco, Infectious Diseases Management Program · Nitrofurantoin - UCSF cystitis guidance; selected source sections, not a full prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For CrCl >60 mL/min, UCSF lists 100 mg orally every 12 hours for cystitis treatment and 100 mg every 24 hours for prophylaxis. Below 60, it describes limited data and advises considering alternatives. Its intermittent and continuous hemodialysis section also advises alternatives because dosing evidence is limited. Exactly 60 is not assigned by the printed >60 and <60 column headings. This is not a professional endorsement of use down to CrCl 30.
Additional summaries stored on this page: 1 official-label, 2 RX List, 4 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.